Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in ...